Cargando…
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
INTRODUCTION: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate, leading to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. In the 6-month double-blind period (DBP) of ILLUMINATE-A, a phase 3, randomized, placebo-controll...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897294/ https://www.ncbi.nlm.nih.gov/pubmed/35257062 http://dx.doi.org/10.1016/j.ekir.2021.12.001 |
_version_ | 1784663360799768576 |
---|---|
author | Hulton, Sally A. Groothoff, Jaap W. Frishberg, Yaacov Koren, Michael J. Overcash, J. Scott Sellier-Leclerc, Anne-Laure Shasha-Lavsky, Hadas Saland, Jeffrey M. Hayes, Wesley Magen, Daniella Moochhala, Shabbir H. Coenen, Martin Simkova, Eva Garrelfs, Sander F. Sas, David J. Meliambro, Kristin A. Ngo, Taylor Sweetser, Marianne T. Habtemariam, Bahru A. Gansner, John M. McGregor, Tracy L. Lieske, John C. |
author_facet | Hulton, Sally A. Groothoff, Jaap W. Frishberg, Yaacov Koren, Michael J. Overcash, J. Scott Sellier-Leclerc, Anne-Laure Shasha-Lavsky, Hadas Saland, Jeffrey M. Hayes, Wesley Magen, Daniella Moochhala, Shabbir H. Coenen, Martin Simkova, Eva Garrelfs, Sander F. Sas, David J. Meliambro, Kristin A. Ngo, Taylor Sweetser, Marianne T. Habtemariam, Bahru A. Gansner, John M. McGregor, Tracy L. Lieske, John C. |
author_sort | Hulton, Sally A. |
collection | PubMed |
description | INTRODUCTION: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate, leading to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. In the 6-month double-blind period (DBP) of ILLUMINATE-A, a phase 3, randomized, placebo-controlled trial in patients with PH1 ≥6 years old, treatment with lumasiran, an RNA interference therapeutic, led to substantial reductions in urinary oxalate (UOx) levels. METHODS: We report data to month 12 in the extension period (EP) of ILLUMINATE-A, including patients who continued lumasiran (lumasiran/lumasiran) or crossed over from placebo to lumasiran (placebo/lumasiran). RESULTS: In the lumasiran/lumasiran group (n = 24), the reduction in 24-hour UOx level was sustained to month 12 (mean reduction from baseline, 66.9% at month 6; 64.1% at month 12). The placebo/lumasiran group (n = 13) had a similar time course and magnitude of 24-hour UOx reduction (mean reduction, 57.3%) after 6 months of lumasiran. Kidney stone event rates seemed to be lower after 6 months of lumasiran in both groups compared with the 12 months before consent, and this reduction was maintained at month 12 in the lumasiran/lumasiran group. At study start, 71% of patients in the lumasiran/lumasiran group and 92% in the placebo/lumasiran group had nephrocalcinosis. Nephrocalcinosis grade improved after 6 months of lumasiran in the lumasiran/lumasiran and placebo/lumasiran groups (13% and 8% of patients, respectively). After an additional 6 months of lumasiran, 46% of patients had improvement in nephrocalcinosis grade within the lumasiran/lumasiran group. Estimated glomerular filtration rate (eGFR) remained stable during the course of lumasiran treatment. The most common adverse events (AEs) related to lumasiran were mild, transient injection-site reactions (ISRs). CONCLUSION: Long-term lumasiran treatment enabled sustained lowering of UOx levels with acceptable safety and encouraging results on clinical outcomes. |
format | Online Article Text |
id | pubmed-8897294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-88972942022-03-06 Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1 Hulton, Sally A. Groothoff, Jaap W. Frishberg, Yaacov Koren, Michael J. Overcash, J. Scott Sellier-Leclerc, Anne-Laure Shasha-Lavsky, Hadas Saland, Jeffrey M. Hayes, Wesley Magen, Daniella Moochhala, Shabbir H. Coenen, Martin Simkova, Eva Garrelfs, Sander F. Sas, David J. Meliambro, Kristin A. Ngo, Taylor Sweetser, Marianne T. Habtemariam, Bahru A. Gansner, John M. McGregor, Tracy L. Lieske, John C. Kidney Int Rep Clinical Research INTRODUCTION: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate, leading to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. In the 6-month double-blind period (DBP) of ILLUMINATE-A, a phase 3, randomized, placebo-controlled trial in patients with PH1 ≥6 years old, treatment with lumasiran, an RNA interference therapeutic, led to substantial reductions in urinary oxalate (UOx) levels. METHODS: We report data to month 12 in the extension period (EP) of ILLUMINATE-A, including patients who continued lumasiran (lumasiran/lumasiran) or crossed over from placebo to lumasiran (placebo/lumasiran). RESULTS: In the lumasiran/lumasiran group (n = 24), the reduction in 24-hour UOx level was sustained to month 12 (mean reduction from baseline, 66.9% at month 6; 64.1% at month 12). The placebo/lumasiran group (n = 13) had a similar time course and magnitude of 24-hour UOx reduction (mean reduction, 57.3%) after 6 months of lumasiran. Kidney stone event rates seemed to be lower after 6 months of lumasiran in both groups compared with the 12 months before consent, and this reduction was maintained at month 12 in the lumasiran/lumasiran group. At study start, 71% of patients in the lumasiran/lumasiran group and 92% in the placebo/lumasiran group had nephrocalcinosis. Nephrocalcinosis grade improved after 6 months of lumasiran in the lumasiran/lumasiran and placebo/lumasiran groups (13% and 8% of patients, respectively). After an additional 6 months of lumasiran, 46% of patients had improvement in nephrocalcinosis grade within the lumasiran/lumasiran group. Estimated glomerular filtration rate (eGFR) remained stable during the course of lumasiran treatment. The most common adverse events (AEs) related to lumasiran were mild, transient injection-site reactions (ISRs). CONCLUSION: Long-term lumasiran treatment enabled sustained lowering of UOx levels with acceptable safety and encouraging results on clinical outcomes. Elsevier 2021-12-11 /pmc/articles/PMC8897294/ /pubmed/35257062 http://dx.doi.org/10.1016/j.ekir.2021.12.001 Text en © 2022 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Clinical Research Hulton, Sally A. Groothoff, Jaap W. Frishberg, Yaacov Koren, Michael J. Overcash, J. Scott Sellier-Leclerc, Anne-Laure Shasha-Lavsky, Hadas Saland, Jeffrey M. Hayes, Wesley Magen, Daniella Moochhala, Shabbir H. Coenen, Martin Simkova, Eva Garrelfs, Sander F. Sas, David J. Meliambro, Kristin A. Ngo, Taylor Sweetser, Marianne T. Habtemariam, Bahru A. Gansner, John M. McGregor, Tracy L. Lieske, John C. Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1 |
title | Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1 |
title_full | Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1 |
title_fullStr | Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1 |
title_full_unstemmed | Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1 |
title_short | Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1 |
title_sort | randomized clinical trial on the long-term efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1 |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897294/ https://www.ncbi.nlm.nih.gov/pubmed/35257062 http://dx.doi.org/10.1016/j.ekir.2021.12.001 |
work_keys_str_mv | AT hultonsallya randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT groothoffjaapw randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT frishbergyaacov randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT korenmichaelj randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT overcashjscott randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT sellierleclercannelaure randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT shashalavskyhadas randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT salandjeffreym randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT hayeswesley randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT magendaniella randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT moochhalashabbirh randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT coenenmartin randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT simkovaeva randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT garrelfssanderf randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT sasdavidj randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT meliambrokristina randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT ngotaylor randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT sweetsermariannet randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT habtemariambahrua randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT gansnerjohnm randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT mcgregortracyl randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 AT lieskejohnc randomizedclinicaltrialonthelongtermefficacyandsafetyoflumasiraninpatientswithprimaryhyperoxaluriatype1 |